Scientists studying why the immune system fails to destroy cancer cells in so many patients have identified a previously unknown molecular brake that silences the body's own cancer-killing defenses from within — a discovery published in the journal Nature on June 9 that researchers say could reshape the development of immunotherapy drugs and provide a path to treatment for millions of patients whose cancers have stopped responding to existing therapies.
The Molecule That Shuts Down the Attack
The brake is a receptor protein called SLAMF6, found on the surface of T cells — the white blood cells that play a central role in the immune system's ability to detect and destroy tumors. The research team, led by Dr. André Veillette at the Montreal Clinical Research Institute and the Université de Montréal, found that SLAMF6 operates through a mechanism that is fundamentally different from every immune checkpoint protein identified before it.
Most existing immunotherapy drugs that target checkpoint proteins — including the blockbuster class that blocks the PD-1 and PD-L1 pathway — work by interrupting signals that cancer cells actively send to T cells to suppress immune activity. SLAMF6 does not require any signal from a tumor at all. It activates itself through direct physical contact between T cells on the same surface, creating an internal feedback loop that exhausts immune cells from within. The result is that T cells stop attacking the tumor not because the cancer has overwhelmed them but because their own molecular architecture has switched them off.
Why This Matters for the One in Three
In the United States, approximately 1.9 million people are diagnosed with cancer each year, according to the National Cancer Institute. Immunotherapy — which harnesses a patient's own immune system to attack tumors rather than relying on chemotherapy — has transformed outcomes for certain cancers over the past decade, particularly advanced melanoma, non-small-cell lung cancer, and some forms of kidney and bladder cancer. But response rates remain deeply uneven. In many solid tumor types, fewer than 20% of patients respond to PD-1 checkpoint inhibitors, and a significant fraction of those who initially respond develop resistance within months.
"This is one of the central unsolved questions in cancer biology," said a senior oncologist at a major cancer research center in the Midwest who reviewed the paper but was not involved in the study. "If SLAMF6 turns out to be as central as this research suggests, it would represent a genuinely new category of therapeutic target — one that operates independently of everything the field has been focused on for the last decade."
The Veillette team tested what happens when SLAMF6 is blocked. Using antibodies developed in the lab to neutralize the receptor, they showed in mouse tumor models that T cells treated with SLAMF6 blockers remained active and aggressive against tumors for significantly longer than untreated cells. More encouragingly, combining the SLAMF6 blocker with existing PD-1 inhibitors produced a synergistic effect — meaning the two mechanisms appear to operate through independent pathways that, when both are interrupted simultaneously, unlock a substantially stronger and more durable immune response than either approach produces alone.
How It Differs From What We Already Have
The distinction between SLAMF6 and previously identified checkpoints has direct implications for how any future drug would be designed and tested. Because SLAMF6 activates without input from the tumor, it represents a type of intrinsic resistance — built into the T cell itself — rather than the adaptive resistance that cancer cells deploy by expressing high levels of PD-L1. That difference means patients whose cancers have evolved to evade PD-1 therapy through any of the currently known mechanisms might still respond to a SLAMF6 inhibitor, because the target is in the immune cell rather than the tumor.
The National Cancer Institute has identified T cell exhaustion — the phenomenon that SLAMF6 now appears to directly drive — as one of its top research priorities in immuno-oncology. The NCI has been funding a broad portfolio of research into the molecular mechanisms of immune cell dysfunction in cancer contexts, and scientists familiar with that portfolio said the SLAMF6 discovery fits squarely into a pattern of findings suggesting that T cell-intrinsic resistance mechanisms may be as important as tumor-extrinsic ones in determining treatment outcomes.
The Road to the Clinic
The research published in Nature is entirely preclinical, conducted in mouse tumor models. The history of oncology immunology is littered with breakthroughs in mice that did not translate directly to humans, and the Veillette team has been careful to frame their findings accordingly. "We want to see this move forward," the team wrote in an accompanying commentary, "but the path from here to a clinical drug involves many steps, many trials, and many uncertainties."
Researchers estimate that human clinical trials are likely three to five years away under a standard development timeline. However, because SLAMF6 blockers could potentially be tested in combination with immunotherapy drugs already approved by the FDA — rather than as stand-alone novel agents requiring a full independent approval pathway — the regulatory process might move faster than for a wholly new class of drug. Combination trials can often benefit from an accelerated review structure, particularly when one component of the combination has an established safety profile in the target patient population.
For the approximately 600,000 Americans who die from cancer each year — and the far larger number living with cancers that have not responded adequately to existing immunotherapy regimens — the discovery adds a new and credible piece to a puzzle that researchers have been assembling for decades. It does not yet represent a treatment. But it represents something equally valuable: a precise molecular explanation for why the treatment keeps failing, and a specific target for making it work.